Lead Sponsor

Calithera Biosciences, Inc

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•1. Documented histological or cytological diagnosis of renal cell carcinoma with a clear-cell component
•2. Adult patients
•3. Karnofsky Performance Score (KPS) ≥ 70%
•4. Measurable Disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
•5. 1-2 lines of prior therapy for advanced or metastatic renal cell carcinoma (RCC) including one anti-angiogenic therapy (any vascular endothelial growth factor \[VEGF\] pathway-targeted agent used either as monotherapy or as a component of a combination regimen) OR the combination regimen of nivolumab + ipilimumab
•6. Adequate hepatic, renal, cardiac and hematologic function

•1. Prior treatment with cabozantinib (or other mesenchymal-epithelial transition \[MET\] inhibitor) or CB-839
•2. Receipt of other anticancer therapy within 2-6 weeks, depending on the treatment
•3. Untreated or active brain metastases or central nervous system cancer, as defined per protocol
•4. Prior gastric surgery, small bowel resection, or other conditions that may impede adequate absorption of oral study drug
•5. Known active infection with human immunodeficiency virus (HIV), Hepatitis B or C virus
•6. Inability to discontinue proton-pump-inhibitor use before randomization
•7. Patients who are pregnant or lactating

Related studies

NCT06500455 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, and more

NCT05969860 · Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, and more

NCT04693377 · Castration-Resistant Prostate Carcinoma, Metastatic Colorectal Carcinoma, and more

NCT06863311 · Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, and more

NCT07123090 · Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer, and more

CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma